EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudie

Cost‐Effectiveness Ratio Analysis of LBBaP Versus BVP in Heart Failure Patients With LBBB

Shengchan Wang, Siyuan Xue, Zhixin Jiang iD, Xiaofeng Hou, Fengwei Zou, Wen Yang, Xiujuan Zhou, Shigeng Zhang, Jiangang Zou, Qijun Shan iD

Pacing and Clinical Electrophysiology · 2024

DOI: 10.1111/pace.15077 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Pacing and Clinical Electrophysiology, 2024. Verfasst von Shengchan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China. Hauptthemen laut MEDLINE: Heart Failure, Cost-Benefit Analysis, Bundle-Branch Block, Cardiac Resynchronization Therapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Project on New 354 Technology of Jiangsu Province, Clinical Competence 353 Improvement Project of Jiangsu Province Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

For the initial treatment strategy for patients with cardiac resynchronization therapy (CRT) indications, whether to choose left bundle branch area pacing (LBBaP) or biventricular pacing (BVP) remains controversial. We aimed to investigate the cost‐effectiveness ratio (CER) of LBBaP and BVP in heart failure (HF) patients with left bundle branch block (LBBB).

Methods

This observational study included HF patients with LBBB who underwent successful LBBaP or BVP. The primary outcomes were echocardiographic response (left ventricular ejection fraction [LVEF] increase ≥5%), LVEF improvement, hospitalization costs, and CER (CER = cost/echocardiographic response rate). Secondary outcomes included other echocardiographic parameters, New York Heart Association (NYHA), N‐terminal pro–B‐type natriuretic peptide (NT‐proBNP), pacemaker parameters, complications, ventricular arrhythmia (VA) events, HF hospitalization (HFH), and all‐cause mortality.

Results

A total of 130 patients (85 LBBaP and 45 BVP) were included (65.6 ± 10.0 years, 70.77% men). The median follow‐up period was 16(12,30), months. Compared with BVP, the LBBaP group showed a greater increase in LVEF (20.2% ± 11.8% vs. 10.5% ± 13.9%; p < 0.001), higher echocardiographic response rate (86.1% vs. 57.8%; p < 0.001), and lower hospitalization costs [$9707.7 (7751.2, 18,088.5) vs. $20,046.1 (18,840.1, 22,447.3); p < 0.0001]. The CER was 112.7 and 346.8 in LBBaP and BVP, respectively. The incremental cost‐effectiveness ratio (ICER = △cost/△echocardiographic response rate) was $−365.3/per 1% increase in effectiveness. LBBaP improved cardiac function more significantly than BVP. There were no significant differences in clinical outcomes.

Conclusions

LBBaP‐CRT is more cost‐effective than BVP, offering greater LVEF improvement, higher echocardiographic response rates, lower hospitalization costs, and more significantly improved cardiac function. These findings need large randomized clinical trials for further confirmation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureCost-Benefit AnalysisBundle-Branch BlockCardiac Resynchronization TherapyHumansMaleFemaleAgedTreatment OutcomeEchocardiographyMiddle Aged

Stichwörter der Autor:innen

biventricular pacingcost‐effectiveness ratioheart failureleft bundle branch area pacingleft bundle branch block

Autor:innen und Institutionen

  • Department of Cardiology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China.
  • Department of Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.
  • Key Laboratory of Targeted Intervention of Cardiovascular Disease, Collaborative Innovation Center for Cardiovascular Disease Translational Medicine, Nanjing Medical University, Nanjing, China.

ORCID-Profile: Zhixin Jiang, Qijun Shan

Förderung

  • National Natural Science Foundation of China
  • Project on New 354 Technology of Jiangsu Province
  • Clinical Competence 353 Improvement Project of Jiangsu Province Hospital

Zitieren

APA

Wang, S., Xue, S., Jiang, Z., Hou, X., Zou, F., Yang, W., Zhou, X., Zhang, S., Zou, J., & Shan, Q. (2024). Cost‐Effectiveness Ratio Analysis of LBBaP Versus BVP in Heart Failure Patients With LBBB. Pacing and Clinical Electrophysiology. https://doi.org/10.1111/pace.15077

Vancouver

Wang S, Xue S, Jiang Z, Hou X, Zou F, Yang W, et al. Cost‐Effectiveness Ratio Analysis of LBBaP Versus BVP in Heart Failure Patients With LBBB. Pacing and Clinical Electrophysiology. 2024. doi:10.1111/pace.15077

BibTeX
@article{Wang2024,
  author = {Wang, Shengchan and Xue, Siyuan and Jiang, Zhixin and Hou, Xiaofeng and Zou, Fengwei and Yang, Wen and Zhou, Xiujuan and Zhang, Shigeng and Zou, Jiangang and Shan, Qijun},
  title = {Cost‐Effectiveness Ratio Analysis of LBBaP Versus BVP in Heart Failure Patients With LBBB},
  journal = {Pacing and Clinical Electrophysiology},
  year = {2024},
  doi = {10.1111/pace.15077}
}
Kostenlos starten →